ImmunoPrecise Antibodies Ltd (NAS:IPA)

$ 0.81 0.0167 (2.11%) Market Cap: 22.11 Mil Enterprise Value: 29.23 Mil PE Ratio: 0 PB Ratio: 0.88 GF Score: 53/100

Q3 2024 Immunoprecise Antibodies Ltd Earnings Call Transcript
Mar 14, 2024

$1.59 (-2.45%)

Earnings
Q2 2024 Immunoprecise Antibodies Ltd Earnings Call Transcript
Dec 14, 2023

$1.45 (+20.83%)

Earnings
Q1 2024 Immunoprecise Antibodies Ltd Earnings Call Transcript
Sep 14, 2023

$2 (-0.99%)

Earnings
Immunoprecise Antibodies Ltd To Participate in an Interview Hosted by Market Radius Research Transcript
Jul 19, 2023
Q4 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Jul 07, 2023

$2.99 (-1.32%)

Earnings
Immunoprecise Antibodies Ltd at Smallcap Discoveries Transcript
Jun 28, 2023
Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q3 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Mar 16, 2023

$3.37 (-10.13%)

Earnings
Q2 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Dec 15, 2022

$4.9 (-8.58%)

Earnings
Q1 2023 Immunoprecise Antibodies Ltd Earnings Call Transcript
Sep 14, 2022

$4.85 (-9.85%)

Earnings
Q4 2022 Immunoprecise Antibodies Ltd Earnings Call Transcript
Jul 29, 2022

$4.23 (-7.03%)

Earnings
Q2 2022 Immunoprecise Antibodies Ltd Earnings Call Transcript
Dec 13, 2021

$5.06 (-9.96%)

Earnings
Immunoprecise Antibodies Ltd LifeScience Webinar Transcript
Apr 28, 2021

Immunoprecise Antibodies Ltd at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 03:00PM GMT

Release Date Price: $3 (-1.32%)

Transcript

Claire Duffy

Jefferies - Analyst

And welcome to the Jefferies Global Healthcare Conference. My name is Claire, and I am with the investment banking team. And this morning, I am pleased to introduce Jennifer Bath, President and CEO of ImmunoPrecise Antibodies.

And with that, I will hand it off to her.

Jennifer Bath

ImmunoPrecise Antibodies Ltd. - CEO and President

Great. Thank you, Claire. And thanks, everyone, for joining me today for this presentation. I'm really excited to share with you this presentation about ImmunoPrecise Antibodies, also known as IPA, and also some of the groundbreaking technology at one of our subsidiaries called BioStrand.

What I'm going to share with you today are technologies in artificial intelligence that are solving some of the world's greatest challenges in data analysis and in drug discovery in general. And we'll be providing you with some evidence to demonstrate exactly how we have tackled those particular challenges.

So before I get started, just first of all, our disclaimer that we are operating

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.